Tafinlar (dabrafenib)

The patient was later hospitalized for "recurrent hemoptysis" and received pemetrexed adjuvant chemotherapy combined with cisplatin...Consequently, a targeted therapy regimen combining low to moderate doses of dabrafenib and trametinib was initiated...Moreover, only one low-grade immune-related adverse event was observed during the course of immunotherapy. Patients with advanced NSCLC and BRAF mutations who cannot tolerate targeted therapy are expected to benefit from immunotherapy.

P2/3, N=30, Not yet recruiting, Cancer Research UK

Collectively, these findings demonstrate that ONC disrupts redox homeostasis, mitochondrial function, and survival signaling in melanoma cells, exerting particularly potent effects in BRAF inhibitor-resistant populations. This study provides mechanistic insight into the anti-melanoma activity of ONC and supports its potential therapeutic application in drug-resistant melanoma.

High-level TRAE management showed a trend toward improved treatment adherence, which was statistically significant for pyrexia. Optional use of an app did not influence treatment adherence.

In this case, rapid tumor shrinkage likely caused weakening and rupture of the trachea, leading to a fatal perforation. This highlights a potential risk of D+T in cases with extensive invasion of vital structures.

Biopsy confirmed a BRAF V600E-mutated lung adenocarcinoma. [¹⁸F]FES PET/CT proved crucial in differentiating synchronous primary malignancies from metastatic spread and guiding targeted therapy with dabrafenib-trametinib.

While the combination of BRAF/MEK inhibitors (e.g., dabrafenib and trametinib) and radiotherapy (RT) is a pivotal therapeutic strategy, it significantly increases the risk of radiation necrosis (RN). Finally, we propose comprehensive strategies to mitigate RN risk, including optimized treatment sequencing, RT dose adjustments, advanced imaging for early detection, and novel approaches for vascular repair. This review underscores prospective studies and standardized guidelines are urgently needed to refine combination strategies and improve outcomes for these patients.

P=N/A, N=120, Recruiting, Fujian Medical University

These tumors express diagnostic GIST markers (c-Kit and DOG1) and show significant response to the BRAF inhibitor dabrafenib. This model recapitulates key histopathological and molecular features of human BRAF-mutant GIST and provides a valuable platform for studying tumor initiation, progression, and therapeutic resistance. Importantly, it allows for preclinical testing of targeted therapies in BRAF GIST, offering new insights into treatment strategies.

Patients received standardized information from their oncologist regarding two adjuvant options - anti-PD1 immunotherapy (nivolumab or pembrolizumab) and targeted therapy (dabrafenib plus trametinib) - before making their treatment choice. Identifying drivers of treatment preference may support more personalized adjuvant strategies. The finding that targeted therapy is favored by younger patients reinforces the relevance of sentinel lymph node biopsy in BRAF-mutated melanoma, despite expanding indications for immunotherapy in earlier stages.

Targeted therapy with dabrafenib and trametinib was initiated, resulting in rapid clinical improvement and complete wound healing. Adult chest wall LCH represents a rare diagnostic challenge due to its malignant radiographic appearance. Histopathologic confirmation, with molecular testing, is essential, and targeted BRAF/mitogen-activated protein kinase kinase (MEK) inhibition may provide an effective therapeutic option when conventional measures fail.